Monday, October 20, 2014
Inquirer Daily News

Novartis' Nebraska problems continue, forcing GlaxoSmithKline recall

The troubled Nebraska manufacturing plant owned by Novartis has translated into a problem for another drug maker as the Lincoln Journal Star reported that GlaxoSmithKline is recalling nearly 400,000 bottles of the blood pressure drug DynaCirc CR.

Novartis' Nebraska problems continue, forcing GlaxoSmithKline recall

The troubled Nebraska manufacturing plant owned by Novartis has translated into a problem for another drug maker as the Lincoln Journal Star reported that GlaxoSmithKline is recalling nearly 400,000 bottles of the blood pressure drug DynaCirc CR.

Novartis produces its own drugs, prescription and over-the-counter, but also manufactures drugs on a contract basis for other manufacturers at the plant near Lincoln. In January, Novartis recalled several of its over-the-counter medicines including Excedrin, Bufferin, GasX and NoDoz.

Endo Pharmaceuticals of Chadds Ford also had to shift production of some of its drugs to an Alabama facility because of the Novartis problems.

The GSK blood pressure medicine in question is the 5 and 10 milligram pills that come in 30-count bottles, according to the recall notice on the U.S. Food and Drug Administration web site.

The reason given mentions "procedural controls related to line clearance during the packaging process at the Novartis Consumer Health site."

The link to the Journal Star story is here.

The link to the FDA page is here, but it's a long list, so scrolling is required.

David Sell
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

For Inquirer.com. Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at dsell@phillynews.com.

David Sell
Business Videos:
Also on Philly.com:
Stay Connected